Matthew K. Fust

Insider Reports History

Location
Novato, CA
Signature
/s/ Tobin Schilke, as attorney-in-fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Matthew K. Fust:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Crinetics Pharmaceuticals, Inc. Director Common Stock 22.8K $1.02M $44.75 26 Sep 2025 Direct
Ultragenyx Pharmaceutical Inc. Director Common Stock 25.9K $985K $37.98 15 May 2025 Direct
Neumora Therapeutics, Inc. Director Common Stock 20.1K $342K $17.03 18 Oct 2024 Direct
Atara Biotherapeutics, Inc. Director Common Stock 18.2K $138K $7.56 10 Jun 2025 Direct
Neumora Therapeutics, Inc. Director Stock Option (Right to Buy) 80K 28 May 2025 Direct
Ultragenyx Pharmaceutical Inc. Director Stock Option (Right to Buy) 10.8K 15 May 2025 Direct
Crinetics Pharmaceuticals, Inc. Director Stock Option (Right to Buy) 2.09K 26 Sep 2025 Direct

Insider Reports Filed by Matthew K. Fust

Symbol Company Period Transactions Value $ Form Type Role Filing Time
CRNX Crinetics Pharmaceuticals, Inc. 26 Sep 2025 3 -$697K 4 Director 30 Sep 2025, 16:41
CRNX Crinetics Pharmaceuticals, Inc. 11 Jun 2025 2 $0 4 Director 13 Jun 2025, 16:30
ATRA Atara Biotherapeutics, Inc. 10 Jun 2025 1 $0 4 Director 12 Jun 2025, 20:39
NMRA Neumora Therapeutics, Inc. 28 May 2025 7 $0 4 Director 30 May 2025, 18:30
RARE Ultragenyx Pharmaceutical Inc. 15 May 2025 2 $0 4 Director 19 May 2025, 18:32
NMRA Neumora Therapeutics, Inc. 13 Feb 2025 6 $0 4 Director 18 Feb 2025, 16:30
NMRA Neumora Therapeutics, Inc. 17 Oct 2024 12 -$244K 4 Director 18 Oct 2024, 18:25
RARE Ultragenyx Pharmaceutical Inc. 18 Jun 2024 2 $0 4 Director 20 Jun 2024, 14:26
NMRA Neumora Therapeutics, Inc. 13 Jun 2024 2 $0 4 Director 14 Jun 2024, 16:13
CRNX Crinetics Pharmaceuticals, Inc. 07 Jun 2024 2 $0 4 Director 11 Jun 2024, 16:19
ATRA Atara Biotherapeutics, Inc. 31 Mar 2024 1 $0 4 Director 02 Apr 2024, 18:13
CRNX Crinetics Pharmaceuticals, Inc. 20 Mar 2024 12 -$1.39M 4 Director 22 Mar 2024, 16:31
RARE Ultragenyx Pharmaceutical Inc. 07 Mar 2024 3 -$620K 4 Director 11 Mar 2024, 12:54
NMRA Neumora Therapeutics, Inc. 14 Sep 2023 1 $0 4 Director 18 Sep 2023, 17:51
NMRA Neumora Therapeutics, Inc. 14 Sep 2023 0 $0 3 Director 14 Sep 2023, 18:57
CRNX Crinetics Pharmaceuticals, Inc. 16 Jun 2023 2 $0 4 Director 21 Jun 2023, 17:00
RARE Ultragenyx Pharmaceutical Inc. 07 Jun 2023 3 -$171K 4 Director 09 Jun 2023, 14:32
ATRA Atara Biotherapeutics, Inc. 31 May 2023 2 $0 4 Director 02 Jun 2023, 19:09
CRNX Crinetics Pharmaceuticals, Inc. 13 Jul 2022 3 -$111K 4 Director 15 Jul 2022, 16:30
RARE Ultragenyx Pharmaceutical Inc. 24 Jun 2022 2 $0 4 Director 28 Jun 2022, 13:52
ATRA Atara Biotherapeutics, Inc. 23 Jun 2022 2 $0 4 Director 27 Jun 2022, 16:48
CRNX Crinetics Pharmaceuticals, Inc. 17 Jun 2022 1 $0 4 Director 21 Jun 2022, 16:46
RARE Ultragenyx Pharmaceutical Inc. 04 Mar 2022 2 $303K 4 Director 08 Mar 2022, 11:25
ATRA Atara Biotherapeutics, Inc. 04 Nov 2021 1 -$260K 4 Director 05 Nov 2021, 16:28
CRNX Crinetics Pharmaceuticals, Inc. 01 Nov 2021 3 -$211K 4 Director 03 Nov 2021, 16:55
CRNX Crinetics Pharmaceuticals, Inc. 08 Sep 2021 3 -$143K 4 Director 09 Sep 2021, 17:00
CRNX Crinetics Pharmaceuticals, Inc. 26 Jul 2021 3 -$88.4K 4 Director 27 Jul 2021, 20:00
CRNX Crinetics Pharmaceuticals, Inc. 19 Jul 2021 3 -$88K 4 Director 20 Jul 2021, 17:00
CRNX Crinetics Pharmaceuticals, Inc. 12 Jul 2021 3 -$94K 4 Director 13 Jul 2021, 17:00
RARE Ultragenyx Pharmaceutical Inc. 24 Jun 2021 2 $0 4 Director 28 Jun 2021, 18:24
CRNX Crinetics Pharmaceuticals, Inc. 22 Jun 2021 1 $0 4 Director 23 Jun 2021, 17:00
ATRA Atara Biotherapeutics, Inc. 08 Jun 2021 2 $0 4 Director 09 Jun 2021, 19:05